Clinical trials: Androgenetic Alopecia
Alopecia, Male Pattern Hair Loss
To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia
The study is a randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the efficacy, safety and tolerability of KX-826 in male subjects with androgenetic alopecia.
- Trial name
- NCT05218642
- Testing
- KX- 826 dosed at 2.5mg, KX-826 dosed at 5mg
- Where
- 10 sites in United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia (AGA)
To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia
This study is a multicenter, randomized, double-blind, vehicle controlled, adaptive design phase 2/3 study to evaluate the efficacy and safety of topical KX-826 solution in Chinese male patients with androgenetic alopecia (AGA).
- Trial name
- NCT06622824
- Testing
- KX-826 0.5% BID, KX-826 1.0% BID
- Where
- China
- Volunteers
- 756 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Male Pattern of Hair Loss, Androgenic Alopecia
Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia
The purpose of this study is to characterize the effect of Minoxidil 5% Foam and Botanical Hair Solution Regimen in men with thinning hair and male pattern hair loss/androgenic alopecia (Norwood III \& IV).
- Trial name
- NCT02460289
- Testing
- Treatment: Minoxidil 5% / Botanical Hair Solution for Men
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Galderma R&D
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012)
To evaluate the ability of injections of Ji Gami(TM) and Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451047
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 7 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Alopecia
Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers
The aim of this study is to determine the bioequivalence of 5 x 0.1 milligram (mg) capsules compared to 1 x 0.5 mg capsule of dutasteride in healthy male subjects.
- Trial name
- NCT01929330
- Testing
- GI198745 0.1 mg, GI198745 0.5 mg
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Male Pattern Baldness, Female Pattern Baldness
Low Level Light Therapy (LLLT) for Hair Growth
A total of 62 participants will receive red light (660 nm) to the scalp through a specially designed light therapy device integrated into a conventional hat.
- Trial name
- NCT03938948
- Testing
- low-level laser/light therapy
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Awareable Technologies Inc
Alopecia, Androgenetic
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
- Trial name
- NCT05244980
- Testing
- TDM-105795
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Technoderma Medicines Inc.
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
This is a Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial designed to evaluate the efficacy and safety of N1087 in women with female pattern hair loss (FPHL).
- Trial name
- MINORA-WOMEN (NCT07303322)
- Testing
- N1087
- Volunteers
- 372 people
- Sponsor
- Eurofarma Laboratorios S.A.
Androgenetic Alopecia, Hair Loss
Treatment of Androgenic Alopecia in Males
The purpose of this study is to evaluate the change in terminal hair count at 16 and 26 weeks compared to baseline measurements.
- Conditions
- Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
- Trial name
- NCT00947219
- Testing
- HairMax LaserComb, Control device
- Where
- 3 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss
Evaluate the ability of Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451099
- Testing
- Autologous cultured dermal cells
- Where
- 6 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenic Alopecia, Hair Loss/Baldness
Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia
The goal of this study is to determine if Xtresse' gummy is safe and may help regrow hair in men with androgenic alopecia (common pattern hair loss).
- Conditions
- Androgenic Alopecia, Hair Loss/Baldness, Hair Thinning
- Trial name
- NCT07637071
- Testing
- Xtressé Hair Growth Gummies
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Androgenetic Alopecia
A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males
The overall purpose of this clinical investigation is to collect data to support a marketing application for over the counter use of the X5 HairLaser with an indication for hair growth.
- Trial name
- NCT02067260
- Testing
- X5 HairLaser
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Spencer Forrest, Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)
The purpose of the study is to evaluate the ability of injections of Ji Gami(TM) or Ji Gami(TM) DO in combination with minoxidil to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451125
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 4 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
Activated PRP for Treatment of Androgenetic Alopecia
A clinical trial to assess the effects and safety of PRP activated with pulsed electrical fields (PEFA-PRP) compared with unactivated PRP when used to treat AGA.
- Trial name
- NCT05348343
- Testing
- Autologous platelet-rich plasma
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Santiste Medical Inc.
Alopecia
AVODART® Alopecia Post-marketing Surveillance (PMS)
Post-marketing surveillance(PMS) to monitor the safety and effectiveness of dutasteride in Korean androgenetic alopecia patients
- Trial name
- AVODART®PMS (NCT01004809)
- Testing
- Dutasteride
- Where
- South Korea
- Volunteers
- 712 people
- Sponsor
- GlaxoSmithKline
Androgenetic Alopecia
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
- Trial name
- NCT04945226
- Testing
- Finasteride 1mg Tablet, IVL3001
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Inventage Lab., Inc.
Androgenetic Alopecia, Female Pattern Baldness
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).
- Conditions
- Androgenetic Alopecia, Female Pattern Baldness, Male Pattern Baldness
- Trial name
- NCT06501924
- Testing
- DA-005, Topical minoxidil 5%, DA-002
- Volunteers
- 516 people
- Sponsor
- Applied Biology, Inc.
Androgenetic Alopecia
Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
The goal of this clinical trial is to assess the safety of the AH-001 drug substance at concentrations of 0.2%, 0.5%, 1%, and 2% in healthy volunteers and male subjects with androgenetic alopecia (AGA).
- Trial name
- NCT06927960
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AnHorn Medicines Co. Ltd.
Alopecia, Male Pattern Hair Loss
To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males
The study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of GT20029 solution.
- Trial name
- NCT06692465
- Testing
- GT20029 Tincture
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,